INAVO120 trial shows inavolisib, palbociclib, and fulvestrant significantly improved overall survival in PIK3CA-mutant ...

Final overall survival (OS) results from the INAVO120 trial (NCT04191499) confirmed that the addition of inavolisib (Itovebi) ...

Despite its expensive valuation and declining estimates, we suggest investors hold LLY stock as the company boasts solid ...

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule ...

The highlights included a potent KRAS inhibitor with impressive tumor growth inhibition in mouse models, a novel PI3Kα inhibitor demonstrating efficacy against key mutations, and a selective ...

Lilly also announced in January that it would be expanding its oncology pipeline by acquiring Scorpion Therapeutics’ PI3Kα inhibitor programme in a deal worth up to $2.5bn, and partnered with Alchemab ...

However, each of the PAM inhibitors only targets a single PAM node such as PI3Kα, AKT, or mTORC1, which is suboptimal because the uninhibited PAM nodes can induce compensatory resistance.

Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed first-quarter estimates for earnings but beat the same for sales.

All cases of elevated transaminases were asymptomatic and fully reversible. Presented updated preclinical data from the company's KRAS, PI3Kα, FGFR2/3 and ErbB2 candidates at the American Association ...

The acquisition of Scorpion Therapeutics’ PI3Kα inhibitor program bolsters Lilly’s oncology franchise, while internal developments like orforglipron—a promising oral GLP-1 candidate—are ...